RedHill Biopharma Ltd.
RDHL · XNASCIK 1553846fmd_1MN6NDBH6S3QTA3JWN0BEYTA07Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
Latest annual · FY2024
Millions- Total revenues
- 8
- Gross profit
- 5
- Operating income
- (15)
- Net income
- (8)
- Free cash flow
- (9)
Latest quarter · Q2 FY2022
Millions- Total revenues
- 18
- Gross profit
- 9
- Operating income
- (9)
- Net income
- (12)
- Free cash flow
- (17)
Daily close · RDHLIEX trades only
May 01, 2025 to Nov 09, 2026 · 250 sessions0.41 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- -54.6%
- Revenue, 5 yearsFY2019 to FY2024
- +5.0%
- Net income, 5 yearsFY2019 to FY2024
- n/m
RedHill Biopharma Ltd. (RDHL) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $8 million | $6.5 million | +23.2% | 20-F 2025-04-10 · proof |
| Gross profit | $4.9 million | $3.1 million | +58% | 20-F 2025-04-10 · proof |
| Operating income | -$14.6 million | $12.6 million | -215.7% | 20-F 2025-04-10 · proof |
| Net income | -$8.3 million | $23.9 million | -134.6% | 20-F 2025-04-10 · proof |
| Cash from operating activities | -$9.4 million | -$35.8 million | 20-F 2025-04-10 · proof | |
| Free cash flow | -$9.4 million | -$35.8 million | 20-F 2025-04-10 · proof | |
| Total assets | $18 million | $23 million | -21.7% | 20-F 2025-04-10 · proof |
| Total liabilities | $22.7 million | $21 million | +8.3% | 20-F 2025-04-10 · proof |
| Cash and cash equivalents | $4.6 million | $5.6 million | -17.1% | 20-F 2025-04-10 · proof |
- What was RedHill Biopharma Ltd. (RDHL)'s revenue in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported revenue of $8 million for fiscal 2024 (the year ended Dec 31, 2024), against $6.5 million the year before (+23.2%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What was RedHill Biopharma Ltd. (RDHL)'s gross profit in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported gross profit of $4.9 million for fiscal 2024 (the year ended Dec 31, 2024), against $3.1 million the year before (+58%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What was RedHill Biopharma Ltd. (RDHL)'s operating income in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported operating income of -$14.6 million for fiscal 2024 (the year ended Dec 31, 2024), against $12.6 million the year before (-215.7%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What was RedHill Biopharma Ltd. (RDHL)'s net income in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported net income of -$8.3 million for fiscal 2024 (the year ended Dec 31, 2024), against $23.9 million the year before (-134.6%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What was RedHill Biopharma Ltd. (RDHL)'s cash from operating activities in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported cash from operating activities of -$9.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$35.8 million the year before. Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What was RedHill Biopharma Ltd. (RDHL)'s free cash flow in fiscal 2024?
- RedHill Biopharma Ltd. (RDHL) reported free cash flow of -$9.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$35.8 million the year before. Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What are RedHill Biopharma Ltd. (RDHL)'s total assets?
- As of Dec 31, 2024, RedHill Biopharma Ltd. (RDHL) reported total assets of $18 million, against $23 million a year earlier (-21.7%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What are RedHill Biopharma Ltd. (RDHL)'s total liabilities?
- As of Dec 31, 2024, RedHill Biopharma Ltd. (RDHL) reported total liabilities of $22.7 million, against $21 million a year earlier (+8.3%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
- What are RedHill Biopharma Ltd. (RDHL)'s cash and cash equivalents?
- As of Dec 31, 2024, RedHill Biopharma Ltd. (RDHL) reported cash and cash equivalents of $4.6 million, against $5.6 million a year earlier (-17.1%). Source: the 20-F filed with the SEC on Apr 10, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RDHL&period_type=annual&limit=5"Information only, not investment advice.